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http://dx.doi.org/10.1016/j.ccr.2014.06.025SUMMARYChloroquine (CQ) has been evaluated as an autophagy blocker for cancer treatment, but it is unknown if it
acts solely by inhibiting cancer cell autophagy. We report that CQ reduced tumor growth but improved the
tumor milieu. By normalizing tumor vessel structure and function and increasing perfusion, CQ reduced hyp-
oxia, cancer cell invasion, and metastasis, while improving chemotherapy delivery and response. Inhibiting
autophagy in cancer cells or endothelial cells (ECs) failed to induce such effects. CQ’s vessel normalization
activity relied mainly on alterations of endosomal Notch1 trafficking and signaling in ECs and was abrogated
by Notch1 deletion in ECs in vivo. Thus, autophagy-independent vessel normalization by CQ restrains tumor
invasion and metastasis while improving chemotherapy, supporting the use of CQ for anticancer treatment.INTRODUCTION
Several clinical trials are evaluating the benefit of the lysosomo-
tropic antimalarial agent chloroquine (CQ), or its derivative hydroxy-
chloroquine, for numerous late-stage cancers, with promising
results (http://www.cancer.gov/clinicaltrials) (Maes et al., 2013).Significance
The antimalaria drug chloroquine (CQ) is tested in oncology. Its
autophagy in cancer cells, but effects on stromal cells are po
cancer cell proliferation by blocking autophagy, CQ targets en
dosomal Notch1 trafficking, thereby inducing tumor vessel nor
hypoxia, CQ impaired cancer cell invasion and metastasis and
These findings provide insight into the anticancermechanisms
190 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.CQ’s anticancer activity is believed to rely on blocking cancer
cell autophagy, a processwherebymolecules and organelles are
encapsulated in autophagosomes and delivered to lysosomes,
where the cargo is degraded and its building blocks are re-
cycled to preserve homeostasis, especially in metabolic stress
(Mizushima et al., 2008). Autophagy in tumors is stimulated inanticancer activity is believed to rely only on the blockade of
orly characterized. We report that besides reducing in vivo
dothelial cells via autophagy-independent alterations of en-
malization. By tightening tumor vessels and reducing tumor
enhanced the delivery and response to chemotherapeutics.
of CQ and identify CQ as a tumor vessel normalization agent.
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Notch1-Reliant Vessel Normalization by Chloroquinenutrient-deprived areas and as a stress response to anticancer
treatment. However, the role of autophagy in cancer is context
and tumor stage dependent, and the mechanisms underlying
the ability of autophagy to modulate invasion and metastasis
are ill defined (Maes et al., 2013; White, 2012).
Being a weak base, CQ is trapped upon protonation in acidic
compartments, like late endosomes (LEs) and lysosomes,where,
by alkalinizing these compartments, it affects fusion events and
disrupts endosomal and autophagic cargo degradation. Thus,
by blocking lysosomal function, CQ can also act via autophagy-
independent mechanisms (Maes et al., 2013), but their nature
remains elusive. A better understanding of how CQ enhances
therapeutic outcomes of conventional chemotherapeutics is
desirable. Here, we investigated whether the anticancer activity
of CQ is mediated by autophagy-dependent or autophagy-inde-
pendent effects on the tumor cells and/or tumor stroma.
RESULTS
CQ Reduces Tumor Growth and Cancer Cell
Proliferation
We focused on melanoma because it is poorly treatable and
reliant on autophagy for its growth (Xie et al., 2013). Consistent
with its autophagy-inhibitory activity, CQ treatment of cancer
cells blocked lysosomal degradation of autophagy-selective
substrates, as shown by the increased levels of LC3II and p62
(Figures S1A and S1B available online) and elevated numbers
and size of LC3+ puncta (Figure S1C). CQ also impaired clono-
genic cancer cell expansion and proliferation, while increasing
cell death, especially under metabolic stress (Figures S1D–
S1I). A375m cells were more sensitive than B16-F10 cells to
the cytotoxic activity of CQ (Figures S1F and S1I). Thus, mela-
noma cells rely on autophagy to sustain growth, and blockage
of their heightened autophagic flux by CQ compromises viability.
To evaluate the effects of CQ on tumor progression, we im-
planted B16-F10 cells and A375m cells in mice. Treatment with
0, 50, or 100 mg/kg/day CQ was initiated when tumors were
100 mm3; tumors were collected when reaching 1,000 mm3
(A375m after 9 weeks for control and 12 weeks for CQ) or
2,000 mm3 (B16-F10 after 20 days for 0 and 50 mg/kg/day CQ
or 26 days for 100 mg/kg/day CQ), and further analysis was per-
formed in size-matched tumors. We refer to 50mg/kg/day as the
low dose and to 100 mg/kg/day as the high dose of CQ.
Using an antibody reacting with CQ revealed an immunoreac-
tive signal in tumors, which increased with higher doses of CQ,
while no signal was detected in untreated tumors (Figure S1J).Figure 1. Effect of CQ on Tumor Necrosis, Intravasation, and Metastas
(A and B) Immunostaining for LC3 in A375m (A) or B16-F10 (B) tumors from control
(C and D) Growth curve of A375m xenografts (n = 11; C) or B16-F10 tumors (n =
(E) Necrotic areas (asterisks within dashed lines) in B16-F10 tumors after CQ versu
is indicated (percentage of total; n = 8–11).
(F) H&E staining of ctrl- and CQ-treated B16-F10 tumors. Arrows indicate residu
(G) Immunostaining for CD31 and endoglin of ctrl- and CQ-treated B16-F10 tum
(CD31endoglin+; arrows) is indicated (n = 8).
(H) RT-PCR analysis for Melan A in blood samples as a measure of circulating tu
(I) Metastatic index in B16-F10 tumor-bearing mice treated with CQ or PBS (n =
(J) Quantification of metastatic nodule area expressed as a percentage of total lun
cells (n = 14–18).
Scale bars represent 50 mm (A and B), 100 mm (E and F), and 25 mm (G). All quan
192 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.Intratumoral CQ levels in vivo detected by gas chromatog-
raphy-mass spectrometry were largely comparable with those
in cancer cells in vitro (Figure S1K). At both doses, CQ reduced
the autophagic flux in both tumors, as evidenced by the
increased LC3II levels and numbers of LC3+ cells (Figures 1A
and 1B; Figures S1L and S1M). In line with the higher sensitivity
of A375m cells to CQ, a low dose of CQ reduced A375m tumor
growth and cancer cell proliferation in vivo, while only a high
dose of CQ reduced these parameters in B16-F10 tumors
(Figures 1C and 1D; Figures S1N and S1O).
CQ Reduces Tumor Necrosis In Vivo but Impairs Cancer
Cell Invasion, Intravasation, and Metastasis
Surprisingly, however, the low dose of CQ reduced rather than
increased cancer cell death in both tumors in vivo, while cancer
cell death in B16-F10 tumors was not affected by the high CQ
dose (Figure 1E; Figures S1P and S1R). These unexpected
findings were likely not due to underdosing of CQ (see above;
Figure S1K). Moreover, cancer cells isolated from tumors of
CQ-treated mice were still sensitive to CQ treatment in vitro,
showing that they had not acquired resistance to CQ (Figures
S1S and S1T). The reduced cancer cell death was also not due
to a change in the expression of protumorigenic signals (Fig-
ure S1U). Thus, contrary to the cytotoxic effect of CQ in vitro,
CQwas less toxic for cancer cells in A375m and B16-F10 tumors
at a low dose in vivo. The discrepancy between CQ’s effects
in vitro and in vivo raised the question whether CQ induced
cancer cell nonautonomous effects in vivo.
We also explored if CQ affected metastasis. Because pilot ex-
periments showed that B16-F10 (but not A375m) tumors were
invasive and metastatic, we used B16-F10 cancer cells. CQ-
treated tumors were less invasive and had more sharply demar-
cated borders at a low dose and even more at a high dose of CQ
(Figure 1F). Double staining for the endothelial cell (EC) marker
CD31and for endoglin, labelingmelanomacells andECs, showed
that CQ reduced the fraction of vessels containing cancer cells
in their lumen as well as the number of cancer cells inside
vessels, suggesting that CQ impaired cancer cell intravasation
(Figure 1G). CQ also lowered the number of circulating cancer
cells (Figure 1H). Counting of pulmonary metastatic nodules,
measuring metastatic nodule size, and calculating themetastatic
index revealed that CQ dose-dependently impaired metastasis
(Figure 1I; Figure S1V). However, CQ did not alter cancer cell
invasion in Matrigel in vitro (Figure S1W) and did not alter
colonization of B16-F10 cells to the lungs after intravenous injec-
tion in an experimental metastasis model (Figure 1J). Thus, theis
(ctrl)-treated mice or frommice treated with a dose of 50 or 100mg/kg/day CQ.
20; D) in ctrl- and CQ-treated mice.
s ctrl (hematoxylin and eosin [H&E] staining); quantification of the necrotic area
al muscle tissue. Dashed line indicates tumor border.
ors. Quantification of the percentage of vessels with intraluminal tumor cells
mor cells in B16-F10 tumor-bearing mice treated with CQ or PBS (n = 10–15).
14–18).
g area from ctrl- and CQ-treatedmice 14 days after tail vein injection of 200,000
titative data are mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S1.
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Figure 2. Effect of CQ on Vessel Structure and Maturation In Vivo
(A–E) B16-F10 tumors from CQ-treated and ctrl mice were immunostained for CD31 (A and B) and aSMA (B) and quantified for tumor vessel density (C) (n = 5),
percentage of tortuous vessels (D) (n = 5), and pericyte-covered vessels (E) (n = 5 or 6).
(legend continued on next page)
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Notch1-Reliant Vessel Normalization by Chloroquineantimetastatic effects of CQ are likely notmediated by a direct ef-
fect on thecancer cells themselves.We then explored if effects on
stromal cells could explain the reduced invasion and metastasis
by CQ.However, CQdid not affect the infiltration of CD45+ leuko-
cytes (Figure S1X) and did not alter the accumulation of platelet-
derivedgrowth factor receptora (PDGFRa+)-positiveora-smooth
muscle actin (aSMA+)-positive cancer-associatedfibroblasts (not
shown). Because CQ reduced tumor cell intravasation and tumor
vessels canaffectmetastasis,weexplored ifCQalteredstructural
and functional properties of tumor vessels.
CQ Induces Tumor Vessel Normalization and Improves
Tumor Vessel Function
A hallmark of many cancers is a structurally and functionally
abnormal vasculature, which reduces tumor perfusion and en-
hances hypoxia, invasion, and metastasis (Carmeliet and Jain,
2011). Indeed, CD31 staining revealed that the vascular architec-
ture in human melanoma biopsies was more chaotic, complex,
and disordered than in healthy skin (Figure S2A). Double staining
for CD31 and the mural cell markers aSMA showed that fewer
pericytes covered blood vessels in human melanoma than
in healthy skin, indicating more immature tumor vessels (Fig-
ure S2A), another sign of vessel disorganization.
Because CQ increased cancer cell death in stressed condi-
tions in vitro, we explored if the antimetastatic effect of CQ in vivo
was due to an increased supply of oxygen and nutrients and
improved EC barrier function via vessel normalization (Carmeliet
and Jain, 2011). Indeed, CQ dose-dependently decreased tumor
vessel density and tortuosity in B16-F10 tumors (Figures 2A, 2C,
and 2D). Whole-mount CD31 staining of thick tumor sections
showed that the vascular architecture was less chaotic and com-
plex in CQ-treated tumors (Figure S2B). CQ also dose-depen-
dently improved vessel coverage by pericytes, a sign of vessel
maturation (Figures 2B and 2E). The vessel normalization effects
of CQwere even more pronounced at a high dose of CQ (Figures
2A–2E).
We also analyzed the EC morphology in tumor vessels by
CD31 staining. Control tumors had thick, irregular vessel walls
with EC extensions protruding in the lumen, whereas CQ-treated
vessels had thin walls with more uniform alignment of ECs
(Figure 2F). Scanning electron microscopy showed a regular,
flat monolayer of ECs in CQ-treated tumor vessels, in contrast
to the more irregular and chaotically organized EC lining in con-
trol vessels (Figure 2G). CQ also increased vascular endothelial
(VE)-cadherin+ adherens junctions in tumor vessels (Figure 2H).
The EC alignment and increase in adherens junctions after
CQ treatment make the EC barrier more impenetrable, which
could explain the reduced cancer cell intravasation upon CQ
treatment. A comparable vessel normalization phenotype was
observed in human A375m melanoma xenografts (Figures
S2C–S2H), indicating that the vascular effects of CQ were not
influenced by the (human or murine) type of malignant cell or
the absence of T cell-mediated immunity.(F) Confocal images of CD31 immunostaining of the vascular network of ctrl- and
lumen; arrowheads indicate smooth thin endothelial lining.
(G) Scanning electron microscopy of B16-F10 tumor vessels from ctrl- and CQ-t
(H) Double staining for VE-cadherin (VE-cadh) and CD31 of B16-F10 tumors from
Scale bars represent 100 mm (A), 50 mm (B, F, and H), and 5 mm (G). All graphs s
194 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.To analyze vessel functionality, we injected tumor-bearing
mice with lectin-fluorescein isothiocyanate (FITC) to label
perfused vessels or dextran-FITC to measure leaky vessels
and then stained B16-F10 and A375m tumor sections for CD31
to identify all vessels (perfused and nonperfused) so that the
percentage of perfused and leaky vessels could be determined.
CQ increased the fraction of perfused lectin-FITC+ CD31+ ves-
sels (Figure 3A; Figures S3A and S3B), while reducing dextran-
FITC leakage (Figure 3B). CQ also dose-dependently decreased
tumor hypoxia (Figure 3C; Figures S3C and S3D). Overall,
CQ improved tumor vessel functionality. The metabolically less
stressed tumor milieu, which renders cancer cells less depen-
dent on autophagy, likely explains why tumor necrosis was
reduced when mice were treated with a low dose of CQ (Fig-
ure 1E; Figure S1P). At a high CQ dose, the prosurvival effect
of vessel normalization was balanced by the increased cytotoxic
effect of CQ, explaining why cancer cell death was no longer
reduced, but comparable with control (see above).
CQ Increases the Delivery and Efficacy of
Chemotherapy
Tumor vessel normalization improves the delivery and efficacy of
chemotherapeutics (Carmeliet and Jain, 2011). Therefore, we
explored if pretreatment with low-dose CQ improved the delivery
and cytotoxicity of cisplatin (CPt). CQ treatment was initiated
when tumors reached 50 mm3 and was repeated daily for
6 days to induce vessel normalization before the administration
of a single dose of CPt (10 mg/kg) and assessment of CPt-
DNA adduct formation. CQ increased CPt-DNA adducts in tu-
mors (Figures 3D and 3E), suggesting improved delivery of the
cytotoxic drug, in line with the increased tumor perfusion.
We then explored whether CQ enhanced the anticancer effect
of a suboptimal CPt dose (2.5mg/kg every other day). Compared
with CPt monotherapy, the combination of CQ with this dose of
CPt caused an anticancer effect accompanied by increased
necrosis (Figures 3F and 3G; Figure S3E). The metastatic index
decreased most when CQwas combined with CPt, but the small
number of metastatic nodules upon CQmonotherapy precluded
us from obtaining a higher significance level (Figure 3H). How-
ever, CQ did not increase the in vitro cytotoxic efficacy of CPt
(Figure 3I), suggesting that chemosensitization by CQ in vivo
was due to effects on vessel normalization (drug delivery).
Similar results in vivo were obtained when combining dacarba-
zine (40 mg/kg) with CQ (Figures S3F and S3G).
ATG5 Silencing in Cancer Cells Does Not Phenocopy
CQ’s Effects
To assess if the tumor and vessel phenotypes of CQ were attrib-
utable to blockade of autophagy in cancer cells, we reduced the
protein levels of the essential autophagy factor ATG5 in B16-F10
cells (by 87 ± 3%; n = 3; p < 0.005). ATG5 silencing reduced
baseline autophagy in cancer cells in vitro and in vivo (Figure 4A;
Figure S4A). Similar to CQ, ATG5 silencing reduced cancer cellCQ-treated B16-F10 tumors. Arrows indicate ECs protruding into the vessel
reated mice.
ctrl- and CQ-treated mice.
how mean ± SEM. *p < 0.05; ***p < 0.001. See also Figure S2.
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Notch1-Reliant Vessel Normalization by Chloroquineproliferation and colony formation and increased cell death
in vitro, especially in metabolic stress (Figures S4B–S4D).
Inhibition of cancer cell-intrinsic autophagy by ATG5 silencing
reduced tumor growth and metastasis (Figure 4B; Figure S4E).
However, ATG5-silenced tumors had larger regions of necrosis,
and only the first 10 layers of perivascular cancer cells survived,
likely because cancer cells located more distantly from vessels
were unable to copewith the increasedmetabolic stress (Figures
4C and 4D). Intriguingly, ATG5-silenced tumors displayed prom-
inent signs of invasion (Figure 4E) and intravasation (Figures 4F
and 4G), comparable with control tumors. Also, ATG5-silenced
cancer cells were nearly unable to colonize the lungs after
intravenous injection (Figure 4H), suggesting that their ability to
survive and colonize was reduced when cancer cell-intrinsic
autophagy was compromised, confirming a recent report
(Peng et al., 2013) and explaining the reduced metastatic poten-
tial of ATG5-silenced B16-F10 tumors.
Importantly, however, ATG5 silencing did not promote tumor
vessel normalization (Figures 4I–4K) and did not improve tumor
perfusion and oxygenation (Figures 4L and 4M; Figures S4F and
S4G). In fact, vessel tortuosity was increased in ATG5-silenced
tumors (Figure 4I; Figure S4G). Thus, like CQ-treated tumors,
autophagy-incompetent cancer cells grew and metastasized
less, but silencing of ATG5 in cancer cells induced effects on tu-
mor vessels in vivo that were opposite to those induced by CQ.
CQ-Mediated Vessel Normalization Is Independent of EC
Autophagy
Tumor vessel normalization can result from an indirect effect on
the angiogenic activity of cancer cells or from a direct effect on
ECs. Because CQ did not alter the production of angiogenic
molecules by cancer cells in vivo (Figure S5A), we studied if
CQ affected ECs in vitro. CQ increased LC3II and p62 levels in
ECs, indicating that it blocked autophagic flux (Figure S5B),
although this increase was less pronounced than in cancer cells.
We monitored CQ’s effects on EC processes using the EC
spheroid sprouting model. In control conditions, CQ decreased
the number and length of the sprouts (Figures 5A–5C). Spheroids
formed more sprouts in hypoxia and fewer sprouts upon starva-
tion, but CQ reduced vascular sprouting in both conditions
(Figures S5C–S5H). Also, CQ decreased EC migration and pro-
liferation (Figures S5I and S5J) and induced EC death only at
high concentrations in metabolic stress (ischemia; Figure S5K).
The effects of CQ on ECs can explain its ability to reduce tumor
vessel density and to induce vessel normalization.
We next explored if CQ’s vessel normalization effect was
due to autophagy inhibition in ECs. We first assessed if ATG5Figure 3. Effect of CQ on Vessel Function and Tumor Chemosensitivit
(A) Micrographs of lectin-FITC-perfused andCD31-stained vessels in ctrl- and CQ
area, percentage of total CD31+ area) (n = 5–7).
(B) Micrographs of FITC-dextran-perfused and CD31-immunostained vessels in c
Quantification of leakage is indicated (CD31dextran+ area, percentage of total d
(C) Micrographs of pimonidazole (PIMO) staining (brown) of hypoxic zones in ctrl- a
of tumor area is indicated (n = 7–12).
(D and E) Immunostaining for CPt-DNA adducts in ctrl- and CQ-pretreated (50 m
(F–H) B16-F10 tumor growth rate (F), tumor necrosis (G), and pulmonary meta
(n = 12–15). #p = 0.07 relative to CQ alone.
(I) Quantification of the fraction of PI+ dead B16-F10 cancer cells in vitro upon C
Scale bars represent 100 mm (A–C) and 50 mm (D). All quantitative data are mean
196 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.silencing in ECs reproduced the vascular phenotype induced
by CQ. Lentiviral transfer of an ATG5-specific small hairpin
RNA (shRNA) lowered ATG5 protein levels by 69% to 75%
(n = 6; p < 0.05) and decreased LC3II formation (Figure S5L).
However, ATG5 silencing did not reduce vessel sprouting (Fig-
ures S5M–S5O) and did not affect EC proliferation andmigration,
or cell death, exceptmoderately inmetabolic stress (Figures S5P
and S5R).
To explore the role of EC autophagy in vivo, we used
Atg5EC-KO mice lacking Atg5 in ECs, obtained by intercrossing
Atg5lox/lox mice (Hara et al., 2006) with VE-cadherin-Cre mice
(Oberlin et al., 2010) and appearing healthy in baseline condi-
tions. B16-F10 tumor growth was reduced in Atg5EC-KO mice,
but the metastatic index was similar (Figures 5D and 5E). Atg5
deletion in ECs did also not affect tumor necrosis and hypoxia
(Figures 5F and 5G) and, importantly, did not induce tumor
vessel normalization (Figures 5H–5O; Figure S5S). In fact, tumor
vessels in Atg5EC-KO mice were smaller, more numerous and
tortuous (Figures 5H, 5J, and 5K), had an abnormal EC lining
(Figure S5S), and were less mature and perfused (Figures 5I
and 5M–5O). Thus, EC-specific deletion of Atg5 caused a tumor
vessel phenotype that is opposite to that induced by CQ.
CQ Promotes Accumulation of Notch1 in LEs of ECs
Because the in vivo effects of CQ on tumor vessel normalization
could not be ascribed to the inhibition of autophagy in ECs, we
investigated how CQ altered EC biology. By virtue of its alkalin-
izing effect on lysosomes, CQ not only inhibits the degradation of
autophagosomes by lysosomes but also interferes with the
endosomal degradative route.We therefore stained ECs for early
endosome (EE) antigen 1 (EEA-1) (a marker of EEs), Rab-11
(labeling recycling endosomes [REs]), and CD63 and LAMP1
(markers of LEs, multivesicular bodies (MVBs), and lysosomes).
CQ did not affect the EE or RE pool, indicating that recycling
routes from EEs to the surface were not affected, but caused
a substantial expansion and swelling of the more acidic LEs,
MVBs, and lysosomes (Figures 6A–6F; Figures S6A and S6B).
Because endosomes are emerging as platforms regu-
lating signaling through receptor internalization (Baron, 2012),
we screened a panel of angiogenic molecules related to vessel
normalization, focusing on transmembrane proteins known to
cycle via endosomal compartments (Eichmann and Simons,
2012). Using CD63 to mark LEs, we explored which molecules
colocalized in LEs after CQ treatment by determining the Pear-
son correlation (PC) coefficient (a biologically significant co-
localization requires a PC coefficient > 0.5). CQ increased LE
colocalization of VE growth factor receptor 1, VE growth factory
-treated B16-F10 tumors. Quantification of perfusion is indicated (CD31+lectin+
trl- and CQ-treated B16-F10 tumors. Arrows indicate sites of vascular leakage.
extran+ area) (n = 4 or 5).
nd CQ-treated B16-F10 tumors. Quantification of PIMO+ area as a percentage
g/kg/day) B16-F10 tumors (D) and quantification (E) (n = 9).
stasis (H) upon single or combined treatment with CQ and CPt (2.5 mg/kg)
Pt treatment in the presence of increasing concentrations of CQ (n = 3).
± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S3.
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Figure 4. Effect of ATG5 Silencing in Tumor Cells on Tumor Growth, Invasion, and Metastasis
(A) Immunoblotting for LC3 and ATG5 protein levels relative to actin in lysates from B16-F10 cancer cells transduced with a shRNA-ATG5 expressing lentivirus
(shATG5) or empty vector (ctrl). Densitometric quantifications of LC3II levels and ATG5 protein levels, relative to actin, are shown (n = 6–8 and n = 7 or 8,
respectively).
(B) Growth curve of primary B16-F10 tumors generated with ctrl or shATG5 cells (n = 9–15).
(C and D) Immunostaining for CD31 and Harris hematoxylin (HH) nuclear counterstaining in ctrl and shATG5 B16-F10 tumors (C) and quantification of the necrotic
area (D). White arrows indicate distance of vessels (CD31 staining) from the necrotic area (asterisk). The border between the viable and necrotic tumor area is
demarcated with a dashed yellow line (n = 9–11).
(E) H&E staining on B16-F10 tumor cells (arrows indicate residual muscle tissue) in ctrl versus shATG5 tumors. The dotted yellow lines demarcate the border
between the tumor and surrounding muscle.
(F and G) Double immunostaining for CD31 and endoglin of ctrl and shATG5 B16-F10 tumors (F) and quantification of the percentage of vessels with intraluminal
tumor cells (CD31endoglin+; arrows) (G) (n = 3; p = NS).
(H) Representative micrographs of lung metastasis after tail vein injection of ctrl or shATG5 B16-F10 tumor cells (H&E staining). Quantification of metastatic area
(percentage of total lung area) is indicated (n = 5).
(I and J) Immunostaining for CD31 of ctrl and shATG5 B16-F10 tumors (I) and quantification (J) (n = 5 or 6).
(K) Scanning electron microscopy of the endothelial lining of vessels from ctrl and shATG5 B16-F10 tumors.
(L andM)Double immunostaining forCD31and lectin of ctrl and shATG5B16-F10 tumors (L) andquantification of percentageCD31+lectin+ vessel area (M) (n = 5–7).
Scale bars represent 200 mm (C and I), 100 mm (E), 50 mm (L), 25 mm (F), 5 mm (K), and 1mm (H). All quantitative data aremean ± SEM. *p < 0.05. See also Figure S4.
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Notch1-Reliant Vessel Normalization by Chloroquinereceptor 2, and PDGFRa, while decreasing colocalization of VE-
cadherin, but their PC coefficients were <0.4 (Figure 6G). CQ
reduced VE-cadherin colocalization in LEs but increased its
cell surface levels (Figure 6G; Figures S6C and S6D), consistent
with the in vivo findings in CQ-treated tumor vessels (Figure 2H).
Of all tested molecules, Notch1 was the one that after CQ co-
localized primarily in LEs (but not in EEs) and had the highest PC
coefficient (0.66 ± 0.01), as evidenced by immunostaining using
an antibody against the carboxyl terminus of Notch1 (Figures 6Gand 6H; S6E-H). This finding was interesting because the vessel
normalization phenotype induced by CQ is similar to the pheno-
type observed by Notch1 activation in tumor ECs (Li et al., 2007).
Indeed, Notch1 promotes EC quiescence (Zhang et al., 2011),
and its inhibition evokes vascular remodeling and hyperbranch-
ing (Dill et al., 2012; Liu et al., 2011; Yan et al., 2010), properties
that could explain CQ’s vessel normalization effects if its activity
relied on Notch1 activation. We therefore focused on the role of
Notch1 signaling in the CQ-mediated vascular effects.Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc. 197
A B
C D E
F
H
J K L M
N O
(legend on next page)
Cancer Cell
Notch1-Reliant Vessel Normalization by Chloroquine
198 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.
Cancer Cell
Notch1-Reliant Vessel Normalization by ChloroquineCQ Alters Endosomal Trafficking of Notch1
Notch1 undergoes proteolysis by ADAM sheddases and g-sec-
retase at the cell surface as well as in EEs and LEs and MVBs
upon internalization and endosomal routing (De Strooper and
Annaert, 2010; Sannerud andAnnaert, 2009). Briefly, ligandbind-
ing to the cell surface-exposed Notch1 extracellular domain,
which forms a heterodimerwith the p120 transmembraneNotch1
fragment, facilitates ectodomain shedding of p120. The newly
generated Notch1 extracellular truncation (NEXT) fragment is
further processed by g-secretase, likely during endosomal rout-
ing, releasing the Notch1 intracellular domain (NICD) that trans-
locates to the nucleus to regulate transcription (Fortini, 2009).
Because CQ did not alter NOTCH1 transcript levels (Fig-
ure S6I), we focused on other mechanisms to explain Notch1
accumulation in LEs and MVBs after CQ administration. Immu-
noblotting showed that CQ dose-dependently increased the
levels of the NEXT fragment, accompanied by a concomitant
increase in NICD, while the full-length 300 kDa (p300) and the
p120 kDa Notch1 species were barely affected (Figure 6I). Cell
surface biotinylation assays revealed that the plasmamembrane
levels of p120 were only slightly affected, while NEXT was unde-
tectable at the surface (Figure 6J), suggesting that initial endoso-
mal routing between the cell surface and EEs was not altered by
CQ and that p120 processing to NEXT occurred downstream of
the constitutive ADAMs-mediated shedding, after internalization
‘‘en route’’ to or within endosomal compartments.
In line, blockage of endocytosis by Dynasore reduced the CQ-
induced Notch1 accumulation in LEs (Figures 6K and 6L). As the
V-ATPase inhibitor bafilomycin A1 (Baf), which like CQ also neu-
tralizes the acidic pH in LEs and lysosomes, increased the coloc-
alization of Notch1 in LEs (Figures 6M and 6N), these results
support a model whereby, following Notch1 internalization and
endosomal trafficking, CQ caused NEXT accumulation in LEs.
CQ Increases Notch1 Signaling in ECs
We then analyzed if the CQ-induced accumulation of Notch1
in LEs/lysosomes caused any changes in NICD signaling. CQ
time-dependently increased NICD protein levels (Figure 7A; Fig-
ure S7A). The magnitude of this increase was lower than the in-
duction by a high concentration (2 mg/ml) of the Notch1 ligand
DLL4 in ECs, but comparable with that induced by a more phys-
iological concentration of DLL4 (0.5 mg/ml) (Guarani et al., 2011;
Harrington et al., 2008) (Figure 7A; Figure S7A). DLL4 induced an
acute butmore transient increase in NICD levels, associatedwith
rapid processing of p120, while CQ caused a slower but more
sustained elevation of NICD over 72 hr (Figure 7A; Figures S7AFigure 5. Effect of Atg5-EC Knockout on Tumor Growth, Invasion, and
(A–C) Representative micrographs of EC spheroid sprouting (A) and quantification
25 mM CQ (n = 19–21).
(D) Growth curve of B16-F10 tumor cells injected into WT or Atg5EC-KO mice (n =
(E) Metastatic index in wild-type (WT) and Atg5EC-KO mice (n = 21–28).
(F) Necrotic areas (asterisks within dashed line) in B16-F10 tumors in WT and A
(percentage of total; n = 10).
(G) Representative micrographs of PIMO staining in B16-F10 tumors from W
(percentage of total; n = 6–9).
(H–M) Immunostaining for CD31 (H) and double immunostaining for CD31 and aS
vessel density (J) (n = 4), percentage of tortuous vessels (K) (n = 4), vessel size (L
(N andO)Double immunostaining for CD31 and lectin of B16-F10 tumors inWTand
Scale bars represent 200 mm (F–H), 10 mm (I), and 100 mm (A and N). All quantitativand S7B). NICD formation after CQ was blunted by the g-secre-
tase inhibitors DAPT (Figure S7C) and Inhibitor X, a finding
confirmed in cells lacking presenilin-1 and presenilin-2, the cat-
alytic components of g-secretase (not shown).
These data imply that NICD formation by CQ relies on NEXT
processing by g-secretase but do not explain why NEXT accu-
mulated after CQ (Figure 7A; Figure S7D). Because CQ did not
affect g-secretase directly, measured with an in vitro enzymatic
activity assay (Figure S7E), we hypothesized that by impairing
lysosomal degradation, CQ caused NEXT to accumulate in LEs
and lysosomes while concurrently providing a pool of substrate
for g-secretase to generate NICD. We thus analyzed the half-life
of endogenous NEXT and NICD in control, DLL4, and CQ condi-
tions in the presence of the protein synthesis inhibitor cyclohex-
imide. Using cycloheximide-treated cells, we also compared
control and DAPT treatments to assess the role of decreased
lysosomal degradation versus g-secretase-mediated process-
ing in the turnover of these Notch1 products.
Quantitative immunoblot densitometry showed that the turn-
over of NEXT and NICD after DLL4 was rapid, consistent with
the reported fast and sequential processing of Notch1 by
ADAMs and of NEXT by g-secretase after ligand stimulation
(Andersson et al., 2011). In line with the aforementioned data,
DAPT reduced the processing of NEXT to NICD in DLL4-stimu-
lated cells (Figures S7F–S7J). In CQ-treated cells, NEXT and
NICD levels also declined over time, but with slower kinetics.
Importantly, however, DAPT further stabilized the CQ-induced
NEXT levels while concomitantly reducing its processing to
NICD (Figures S7F–S7J). Thus, because NEXT accumulates in
CQ-treated ECs because of reduced lysosomal degradation
(prolonging its half-life) andNEXT is the substrate of g-secretase,
the latter is able to generate larger amounts of NICD.
The predominant NICD bands generated in response to DLL4
displayed a slower SDS-PAGE mobility pattern than the one
formed after CQ (Figure 7A), suggesting distinct posttranslational
modifications (Fortini, 2009), a model we explored by using the
proteasome inhibitor lactacystin. In control and DLL4-treated
conditions, lactacystin evoked an accumulation of NICD bands
with a similar slower mobility pattern (Figure S7K). In contrast,
after CQ administration, the faster migrating NICD form that
predominantly accumulates over timewas not increased by lacta-
cystin (Figure S7K). These results combined with the shorter half-
life of NICD in DLL4 conditions (Figures S7F–S7J) suggest that
the upper bands represent posttranslational modifications of
NICD (possibly phosphorylation, ubiquitinylation) known to target
NICD for proteasomal degradation (Andersson et al., 2011). TheyMetastasis
of sprout number (B) and sprout length (C) in the absence or presence of 10 or
23–32).
tg5EC-KO mice (H&E staining); quantification of the necrotic area is indicated
T and Atg5EC-KO mice. Quantification of PIMO+ hypoxic area is indicated
MA (I) of B16-F10 tumors in WT and Atg5EC-KO mice and quantification of tumor
) (n = 4), and percentage of pericyte-covered vessel (M) (n = 6).
Atg5EC-KOmice (N) and quantification of%CD31+lectin+ vessel area (O) (n = 5).
e data are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S5.
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Figure 6. Effect of CQ on Notch1 Localization and Signaling in the LEs
(A–F) Immunostaining (A, C, and E) and quantifications (B, D, and F) of ECs for the early endosomal marker EEA-1 (A and B), the recycling endosomal marker
Rab11 (C and D), or the late endosomal compartment (LE/MVB) marker CD63 (E and F). Insets in (A), (C), and (E): Larger magnification of boxed areas (n = 10).
(G) Quantification of the colocalization of CD63 and angiogenic molecules upon double immunostaining (n = 10).
(H) Double immunostaining for Notch1 (using the C-terminal anti-Notch1 antibody) and CD63 in ctrl- and 25 mMCQ-treated HUVECs. Insets: Larger magnification
of the boxed areas. The quantification of the colocalization (PC coefficient) is indicated (n = 10).
(I) Immunoblotting of EC lysates for different Notch1 cleavage products in ECs treated with CQ (5–25 mM). Densitometric quantification for the different CQ
concentrations relative to control (0) is indicated (n = 3).
(J) Immunoblotting for different Notch1 cleavage products of total EC lysates and biotin-bound fraction of ECs treated with CQ (25 mM) and subjected to cell
surface biotinylation before extraction. Densitometric quantification of CQ relative to ctrl is indicated (n = 4).
(K and L) Double immunostaining for Notch1 andCD63 (K) and quantification of Notch1+ area (L) of ECs in ECs treated with 25 mMCQalone or in combination with
the endocytosis blocker Dynasore. Insets: Larger magnification of the boxed areas (n = 10).
(M and N) Double immunostaining (M) and quantification (colocalization) (N) for Notch1 and CD63 of ctrl and the V-ATPase inhibitor Baf-treated ECs. Insets:
Larger magnification of the boxed areas (n = 10).
Scale bars represent 10 mm in all micrographs. All quantitative data are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S6.
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processed,while theNICD formafterCQmaybe lessprone topro-
teasomal degradation, an assumption requiring confirmation.
Despite these differences, NICD generated after CQ accumu-
lated in the nucleus and was transcriptionally active, as analyzed
by immunoblotting, immunostaining, and use of a NICD luciferase
reporter assay (Figures7B–7D).Moreover, increasedmRNA levels
of the Notch1-target genes HEY1 and HES1 (Figures 7E and 7F)
and a pHES-1 luciferase reporter assay (Figure S7L) confirmed
that CQ and DLL4 elevated Notch1 signaling with kinetics reflect-
ing those of NICD induction following each particular treatment.
Baf also increased nuclear accumulation of NICD (Figure S7M),200 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.further strengthening the finding that NICD levels are elevated by
compromising lysosomal function. CQ’s effect on NICDwas spe-
cific, as CQ did not affect the levels of the Notch1 ligands DLL4 or
Jagged-1 (Figure S7N). In line with reports that Notch signaling in
melanoma is constitutively activatedbyoncogenic signals (Mu¨ller,
2012), CQ did not elevate NICD levels in melanoma cells at con-
centrations that were effective in ECs (not shown).
Notch1 Signaling in ECs Is Required for CQ-Induced
Vessel Normalization
To verify the importance of Notch1 in mediating CQ’s effects on
ECs, we silenced Notch1 and blocked NICD production (and
AB C
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F
(legend on next page)
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abolished CQ-mediated induction of NICD (Figures S7C and
S7O) and CQ’s inhibitory effect on vessel sprouting in EC spher-
oids (Figure 8A; Figures S8A and S8B), thus validating Notch1 as
a major target of CQ in ECs. Silencing of the other Notch recep-
tors did not abrogate CQ’s inhibitory effects on vessel sprouting
(Figures S8C–S8F).
To confirm the role of endothelial Notch1 signaling in
mediating CQ’s effect on tumor vessel normalization in vivo,
we analyzed the effect of CQ on tumor vessels in mice lacking
Notch1 in ECs (Notch1EC-KO). These mice were generated by
intercrossing Notch1lox/lox mice (Radtke et al., 1999) with
VE-cadherin(PAC)-CreERT2 mice, an EC-specific inducible Cre-
driver line (Benedito et al., 2012), and treating them with tamox-
ifen for 7 days. RT-PCR revealed decreasedNotch1 levels in ECs
isolated fromNotch1EC-KOmice (by 74 ± 5%; n = 5). Treatment of
isogenic Notch1EC-KO mice with 50 mg/kg/day CQ did not affect
B16-F10 tumor growth (Figure 8B). Notably, EC loss of Notch1
completely abrogated the inhibitory effects of CQ on metastasis
and tumor necrosis (Figures 8C and 8D).
EC-specific deficiency of Notch1 itself already affected the tu-
mor vasculature. Indeed, tumors from Notch1EC-KO mice were
more hypoxic and formed more numerous, more tortuous, less
mature, and hypoperfused vessels (Figures 8E–8J). Importantly,
however, CQ treatment of Notch1EC-KO mice failed to reduce
tumor vessel density, tortuosity, and tumor hypoxia and failed
to increase vessel maturation and perfusion (Figures 8E–8J).
These findings that endothelial loss of Notch1 completely abro-
gated the inhibitory effects of CQ on tumor vessel normalization
indicate that the vascular effects of CQ primarily relied onNotch1
signaling in vivo.
DISCUSSION
CQ is used as an autophagy blocker in anticancer treatment,
but it is unknown if CQ exerts its effects solely by inhibiting
autophagy in cancer cells. We identified an effect of CQ on tumor
vessel normalization, which helps explain its antimetastatic and
chemotherapy-enhancing actions.
Using two metastatic melanoma models, relying on height-
ened autophagy for their growth (Noman et al., 2011; Xie et al.,
2013), we show that the anticancer activity of CQ is not only
reliant on direct cancer cell killing through blockage of prosur-
vival autophagy (the sensitivity to this killing effect may vary be-
tween individual cancer cell types) but also or primarily relies on
an effect on tumor vessels. Indeed, even at a dose that was inef-
fective to reduce tumor growth (50 mg/kg/day), CQ already
modified the tumor milieu by improving tumor perfusion and
oxygenation. Because metabolic stress stimulates autophagy,Figure 7. Effect of CQ on Notch1 Signaling in ECs
(A) Immunoblotting for NICD, p120, and NEXT of ECs treated with CQ (25 mM) or
(B) Immunoblotting for NICD in nuclear and cytoplasmic extracts of ECs treated
(lamin) and cytoplasmic (glyceraldehyde 3-phosphate dehydrogenase) fractions
(C) Immunostaining for NICD in ctrl- and CQ-treated cells (DAPI nuclear staining).
nucleus is indicated. The scale bar represents 10 mm.
(D) RBPj dual luciferase reporter assay in ECs in response to CQ (25 mM) or DLL
(E and F) RT-PCR analysis of the Notch target transcripts HEY1 (E) and HES1 (F) in
All quantitative data are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See als
202 Cancer Cell 26, 190–206, August 11, 2014 ª2014 Elsevier Inc.cancer cells growing in these CQ-treated tumors likely relied
less on autophagy because they had access to more abundant
oxygen and nutrients and were thus less sensitive to CQ’s anti-
proliferative and cytotoxic activity.
CQ reduced tumor hypoxia, cancer cell invasion, intravasa-
tion, and spreading and improved the delivery and efficacy of
chemotherapeutics. The better perfused, less chaotic, and tight-
ened EC barrier in vivo observed after CQ treatment can explain
the reduction in cancer cell intravasation and the number of
circulating cancer cells (Mazzone et al., 2009). Moreover,
because tumor hypoxia promotes metastasis (Carmeliet and
Jain, 2011), CQ’s effect on improving tumor oxygenation
may contribute to the decreased cancer cell invasiveness and
dissemination. Consistently, tumor vessel normalization often
does not affect the size of primary tumors, but its benefit relates
to reduction of metastasis and to the improved drug delivery and
efficiency of chemotherapy (Carmeliet and Jain, 2011). A previ-
ous study reported that CQ is ‘‘vasculoprotective’’ (Hagihara
et al., 2000) but did not assess vessel normalization. Further
support that CQ’s antimetastatic effects are likely mediated by
cancer cell-nonautonomousmechanisms is provided by findings
that CQ did not prevent colonization of cancer cells to the lungs
after intravenous injection and invasion of cancer cells in vitro.
Though CQ might have other antimetastatic effects that were
not explored here, CQ at least partly prevented metastasis by
promoting vessel normalization.
Unlike CQ, ATG5 knockdown in cancer cells did not improve
tumor oxygenation and did not affect cancer cell invasion and in-
travasation but did increase tumor cell death. Except for the
reduced tumor growth andmetastasis, ATG5 knockdown overall
did not phenocopy the effects of CQ on the tumor stroma.
Regarding the mechanisms of metastasis, ATG5-silenced
cancer cells also failed to colonize the lungs after intravenous
injection, most likely because of their increased vulnerability to
anoikis (Fung et al., 2008). In contrast, CQ reduced metastasis
by impairing intravasation.
Blocking EC autophagy by ATG5 knockdown did also not
phenocopy CQ-induced EC responses in vitro, nor did it affect
tumor vessels in vivo. Although genetic loss of Atg5 in ECs
delayed tumor growth, it did not reduce the metastatic index
and failed to evoke vessel normalization and improve tumor
oxygenation. On the contrary, tumor vessels in Atg5EC-KO
mice displayed smaller lumens and increased density and tortu-
osity and exhibited reduced vessel maturation and perfusion.
Thus, genetic loss of autophagy in ECs exacerbated the chaotic
and functionally abnormal tumor vasculature, while CQ pro-
duced the opposite effect. Overall, blockage of autophagy in
ECs or cancer cells cannot explain CQ’s ability to normalize
tumor vessels.DLL4 (0.5 mg/ml) for 12, 24, 48, or 72 hr (n = 3).
with CQ (25 mM) or DLL4 (0.5 mg/ml) for 24 hr. Loading control of the nuclear
is shown. Densitometric quantification is shown below the lanes (n = 4).
Insets are magnifications of the boxed areas. Quantification of NICD+ area per
4 (0.5 mg/ml) after 12, 24, 48, or 72 hr (n = 3).
ECs treated with CQ (25 mM) or DLL4 (0.5 mg/ml) for 12, 24, 48, or 72 hr (n = 6).
o Figure S7.
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Notch1-Reliant Vessel Normalization by ChloroquineThe vessel normalization effect of CQ phenocopied the
vascular effects induced by Notch1 activation in tumor ECs,
characterized by fewer but more perfused vessels, resulting in
decreased intratumoral hypoxia (Li et al., 2007). In line, CQ
normalized tumor vessels largely by increasing Notch1 signaling
in ECs. Indeed, CQ reduced EC proliferation and migration and
impaired vessel sprouting in vitro, known vascular effects of
Notch (Phng and Gerhardt, 2009). CQ increased nuclear accu-
mulation and the transcriptional activity of NICD, while Notch1
inhibition or knockdown abrogated CQ’s effects in vitro. Our
findings do not exclude the possibility that CQ can affect vessel
normalization by regulating additional molecular pathways or by
affecting other stromal cells. Importantly, however, all effects of
CQ on tumor oxygenation, vessel normalization, tumor necrosis,
andmetastasis were completely reverted in mice lackingNotch1
in ECs. These findings provide compelling evidence for an auto-
phagy-independent and Notch1-requiring mechanism of CQ to
promote normalization of the tumor vasculature.
How then does CQ increase Notch1 signaling in ECs? Pro-
cessing of Notch1 to NICD by g-secretase can occur at different
sites, from the plasma membrane up to endosomal compart-
ments. Notably, CQ induced a prominent accumulation of
Notch1 in LEs and lysosomes, degradative compartments that
are important signaling hubs, a process that did not require
activation of Notch1 by its ligands. Different experimental ap-
proaches support the following model: CQ has no effect on
cell surface-localized shedding of p120 by ADAMs and thus
does not affect p120 levels. Instead, by compromising LE and
lysosomal function (through alkalinization) and reducing lyso-
somal degradation, CQ induces an accumulation of NEXT,
thereby providing a larger source of this substrate for g-secre-
tase, which thus can generate higher amounts of NICD. This
results in sustained activation of Notch1 signaling, sufficient to
induce tumor vessel normalization.
Activation of Notch1 signaling by CQ is different from that
induced by DLL4. In this case, ligand binding induces shedding
of p120 by ADAMs to produce NEXT. Because LE and lysosomal
functions are normal, further proteolysis by g-secretase can
keep pace with the increased production of NEXT, preventing
its accumulation and leading to a more transient increase in
NICD and Notch1 signaling.
Tumor vessel normalization improves the delivery and efficacy
of chemotherapy (Carmeliet and Jain, 2011). We show a greater
tumor-inhibitory effect when CQ is combined with chemo-Figure 8. Effect of Genetic Deficiency of Notch1 in ECs on CQ Phenoty
(A and B) Representative micrographs (A) and quantification of sprout length (B) (n
scrambled shRNA-treated ECs (ctrl) in the presence or absence of CQ.
(C) Growth curve of B16-F10 tumors in WT mice and in Notch1EC-KO mice treate
(D) Metastatic index in B16-F10 tumor-bearing WT and Notch1EC-KO mice treate
(E) Micrographs of H&E staining of necrotic areas (asterisks within dashed line
Quantification of necrotic tumor area is indicated (percentage of total; n = 4–6).
(F) Micrographs of PIMO staining of hypoxic zones in B16-F10 tumors from WT
percentage of total; (n = 5–9).
(G–J) Immunostaining for CD31 and aSMA of B16-F10 tumors fromWT and Notc
vessel area expressed as percentage of the total area (H), percentage of tortuou
(K) Micrographs of lectin-FITC-perfused and CD31-stained vessels in B16-F10 tu
perfusion (CD31+lectin+ area, percentage of total CD31+ area) is included (n = 3)
Scale bars represent 200 mm (A, E, and F) and 100 mm (G and K). All data are me
quantified relative to WT ctrl, unless indicated with the bar. See also Figure S8.
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in vitro but only in vivo, CQ’s effect on the chemoresponse is
likely due to its cancer cell-extrinsic vessel normalization effects,
which increase the delivery of cytotoxic agents to the tumor core
because of improved perfusion. Vessel normalization also re-
duces the interstitial fluid pressure in tumors, thereby facilitating
egress of cytotoxic agents from the blood into the tumor intersti-
tium (Leite de Oliveira et al., 2012). Also, because the efficacy of
cytotoxic agents relies on oxygenation to generate oxygen rad-
icals, CQ improved the chemotherapy response by reducing tu-
mor hypoxia as well. Consistently, CQ enhanced the anticancer
effect of radiotherapy and lowered tumor hypoxia (Rouschop
et al., 2010). Although the mechanisms were not studied in this
report, on the basis of our results, the improved tumor oxygena-
tion might have been due to CQ-mediated vessel normalization.
Vessel normalization also facilitates the access of immune cells
to tumors and converts the immunosuppressive into an immu-
nostimulatory milieu (Huang et al., 2012). Noteworthy, CQ poten-
tiates antitumor responses induced by vaccination or immune
cell infiltration (Liang et al., 2012; Noman et al., 2011). It will be
interesting to explore if CQ, besides its immunodampening
effects (Townsend et al., 2012), can regulate tumor immunity
via effects on vessel normalization.
A recent survey on the use of CQ and hydrochloroquine as
mainstay treatments for autoimmune pathologies commented
that these antimalarial drugs also exert vasculoprotective, antith-
rombotic, and possibly even antineoplastic effects, while warn-
ing caution against rare retinal toxicity events (Lee et al., 2011).
The property of CQ as a clinically approved drug to induce
persistent tumor vessel normalization makes this agent espe-
cially attractive for anticancer therapy.EXPERIMENTAL PROCEDURES
Detailed methods are described in Supplemental Experimental Procedures.
Cell Culture and In Vitro Functional Assays
Human umbilical vein ECs (HUVECs) and cancer cells were cultured as
described in Supplemental Experimental Procedures. Autophagic flux detec-
tion was determined via immunoblotting for LC3 and p62 or immunostaining
of LC3. Cell death was analyzed by propidium iodide (PI) exclusion and
quantified by flow cytometry. Proliferation was quantified by measuring
[3H]-thymidine incorporation. To assess clonogenic growth, the number of
colonies formed by single cells was analyzed after 7 days. EC spheroids
were embedded in collagen gel and cultured for 24 hr to induce sprouting.pes
= 20) of spheroids of Notch1-silenced (Notch1KD) ECs compared with control
d with CQ (50 mg/kg/day) or PBS (n = 12–14).
d with or without CQ (n = 41–54).
s) in B16-F10 tumors in WT versus Notch1EC-KO treated with CQ or vehicle.
and Notch1EC-KO mice treated with vehicle or CQ. Quantification is indicated
h1EC-KO mice, treated with vehicle or CQ (G) and quantification of CD31+ tumor
s vessels (I), and percentage of pericyte-covered vessels (J) (n = 4).
mors in WT and Notch1EC-KO mice treated with vehicle or CQ. Quantification of
.
an ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Significance for all conditions is
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Notch1-Reliant Vessel Normalization by ChloroquineNumber and sprout length were analyzed with Image J software (NIH).
A scratch wound was applied on confluent EC monolayers in 24-wells
after overnight CQ pretreatment. Migration distance was measured with
Image J software. Cancer cells were seeded on Matrigel, and invasion
was quantified after 48 hr by measuring the area of cancer cell invasion
into Matrigel.
Treatments
CQ- or shRNA-mediated human ATG5 or murine ATG5 targeting were used
to inhibit autophagy. For Notch pathway activation, cells were grown on
plates coated with recombinant human DLL4 extracellular domain. Inhibi-
tion of Notch activity was achieved by culturing cells in the presence
of 10 mM DAPT or by shRNA-mediated Notch1,2,3,4 silencing. Baf and
Dynasore were used to block the vacuolar H+ ATPase and internalization,
respectively.
RT-PCR, Immunoblotting, and Immunocytochemistry
mRNA expression was analyzed by quantitative RT-PCR. Immunoblotting
and immunostaining were performed using methods and antibodies listed in
Supplemental Experimental Procedures.
Mouse Models
Animal procedures were approved by the Institutional Animal Care and
Research Advisory Committee (KU Leuven) (ECD118/2013) and were per-
formed in accordance with the institutional and national guidelines and regu-
lations. To assess subcutaneous tumor growth, 150,000 B16-F10 (murine) or
300,000 A375m (human) melanoma cells were injected subcutaneously into
the right flanks of immunocompetent syngeneic (C57/Bl6) or immunodeficient
(nu/nu) mice, respectively. Tumor volumes were measured three times per
week with a caliper using the formula V = p 3 [d23 D]/6, where d is the minor
tumor axis and D is the major tumor axis. For experimental metastasis,
200,000 B16-F10 cells were injected in the tail veins of C57/Bl6 mice, and after
14 days, mice were sacrificed and lungs collected.
Patient Samples
Biopsies from melanoma and healthy skin were collected at the university
hospital of Leuven with patients’ informed consent, in accordance with the
Declaration of Helsinki and with the approval of the Medical Ethics Committee
of the university hospital.
Statistics
Data displayed in the figures and text represent mean ± SEM of representative
experiments unless otherwise stated; each experiment was repeated at least
three times and involved at least triplicate measurements. Statistical signifi-
cance was calculated by standard t test or ANOVA. A p value < 0.05 was
considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2014.06.025.
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